Bronchopulmonary Dysplasia Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bronchopulmonary Dysplasia pipeline constitutes 10+ key companies continuously working towards developing 12+ Bronchopulmonary Dysplasia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bronchopulmonary Dysplasia Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchopulmonary Dysplasia Market.

The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Bronchopulmonary Dysplasia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key takeaways from the Bronchopulmonary Dysplasia Pipeline Report:
• Companies across the globe are diligently working toward developing novel Bronchopulmonary Dysplasia treatment therapies with a considerable amount of success over the years.
• Bronchopulmonary Dysplasia companies working in the treatment market are Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others, are developing therapies for the Bronchopulmonary Dysplasia treatment
• Emerging Bronchopulmonary Dysplasia therapies in the different phases of clinical trials are- OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others are expected to have a significant impact on the Bronchopulmonary Dysplasia market in the coming years.
• In May 2026, Phase IIb/III Clinical Trial Recruiting: Airway Therapeutics is actively enrolling patients in the ZEL-003 Phase IIb/III trial to evaluate zelpultide alfa (rhSP-D) as a preventive therapy for Bronchopulmonary Dysplasia (BPD) in high-risk premature infants. The study is investigating the treatment's potential to lower the occurrence of moderate-to-severe BPD and reduce mortality in this vulnerable patient population.
• In March 2026, Phase IIb Trial Protocol Published: A Phase IIb study protocol was released for OHB-607 (rhIGF-1/rhIGFBP-3), evaluating its potential as a preventive treatment for Bronchopulmonary Dysplasia (BPD) in preterm infants. The trial is designed to support healthy lung development and minimize the risk of long-term respiratory complications linked to premature birth.
• In January 2026, Phase II HULC-2 Trial Update: Investigators progressed the Phase II HULC-2 study, which is assessing various doses of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in extremely premature infants at elevated risk of Bronchopulmonary Dysplasia (BPD). The trial aims to evaluate the therapy's safety profile, enhance respiratory health outcomes, and decrease reliance on prolonged mechanical ventilation.
• In August 2025, Regulatory Milestone: Airway Therapeutics secured approval from the European Medicines Agency's Pediatric Committee (PDCO) for the Pediatric Investigation Plan of zelpultide alfa, marking an important step forward in the progression of its global Phase IIb/III clinical program for very preterm infants at risk of developing Bronchopulmonary Dysplasia (BPD).

Bronchopulmonary Dysplasia Overview
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants, especially those born very early, usually before 28 weeks of gestation. This condition is a consequence of lung injury and inflammation, often resulting from the use of mechanical ventilation and oxygen therapy, which are common interventions in the care of premature infants with respiratory distress syndrome.

Explore the latest Bronchopulmonary Dysplasia pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Bronchopulmonary Dysplasia Clinical Trials
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Bronchopulmonary Dysplasia Drugs Under Different Phases of Clinical Development Include:
• OHB-607: Chiesi Farmaceutici S.p.A.
• AVR-48: AyuVis Research
• AT-100: Airway Therapeutics, Inc
• UMC119-01: Meridigen Biotechnology
• Pneumostem: Medipost Co., Ltd.
• OHB-607: Oak Hill Bio Ltd.
• INOmax: Mallinckrodt
• Furosemide Cohort 1: The Emmes Company, LLC
• Inhaled Nitric Oxide: Mallinckrodt
• PNEUMOSTEM®: Medipost Co Ltd.
• Curosurf: Chiesi Farmaceutici S.p.A.

Bronchopulmonary Dysplasia Route of Administration
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bronchopulmonary Dysplasia Molecule Type
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment
• Bronchopulmonary Dysplasia Assessment by Product Type
• Bronchopulmonary Dysplasia By Stage and Product Type
• Bronchopulmonary Dysplasia Assessment by Route of Administration
• Bronchopulmonary Dysplasia By Stage and Route of Administration
• Bronchopulmonary Dysplasia Assessment by Molecule Type
• Bronchopulmonary Dysplasia by Stage and Molecule Type

DelveInsight's Bronchopulmonary Dysplasia Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bronchopulmonary Dysplasia product details are provided in the report. Download the Bronchopulmonary Dysplasia pipeline report to learn more about the emerging Bronchopulmonary Dysplasia therapies
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Pipeline Analysis:
The Bronchopulmonary Dysplasia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Bronchopulmonary Dysplasia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchopulmonary Dysplasia Treatment.
• Bronchopulmonary Dysplasia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bronchopulmonary Dysplasia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchopulmonary Dysplasia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bronchopulmonary Dysplasia drugs and therapies
https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchopulmonary Dysplasia Pipeline Market Drivers
• Increased Research and Development Activities, new and developed Robust Pipeline are some of the important factors that are fueling the Bronchopulmonary Dysplasia Market.

Bronchopulmonary Dysplasia Pipeline Market Barriers
• However, complications with available treatment options, no Bronchopulmonary Dysplasia approved therapy, lack of a reliable methods for identifying pediatric patients at risk and other factors are creating obstacles in the Bronchopulmonary Dysplasia Market growth.

Scope of Bronchopulmonary Dysplasia Pipeline Drug Insight
• Coverage: Global
• Key Bronchopulmonary Dysplasia Companies: Chiesi Farmaceutici S.p.A., AyuVis Research, Airway Therapeutics, Inc, Meridigen Biotechnology, Medipost Co., Ltd., Oak Hill Bio Ltd., Mallinckrodt, The Emmes Company, LLC, Medipost Co Ltd., and others
• Key Bronchopulmonary Dysplasia Therapies: OHB-607, AVR-48, AT-100, UMC119-01, Pneumostem, OHB-607, INOmax, Furosemide Cohort 1, Inhaled Nitric Oxide, PNEUMOSTEM®, Curosurf, and others
• Bronchopulmonary Dysplasia Therapeutic Assessment: Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies
• Bronchopulmonary Dysplasia Market Dynamics: Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.